Jafron Biomedical Co

Jafron Biomedical Co AAQS

The The AAQS of Jafron Biomedical Co (300529.SZ) as of Oct 24, 2026 is 7. In the previous year, The AAQS was 7.00 — a change of 0.00% (lower).

AAQS

7

YoY

0.00%

Last updated:

Jafron Biomedical Co has a current AAQS of 7.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Jafron Biomedical Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Jafron Biomedical Co AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
7.00 CNY
Jan 1, 2019
7.00 CNY
Jan 1, 2020
7.00 CNY
Jan 1, 2021
7.00 CNY
Jan 1, 2022
7.00 CNY
Jan 1, 2023
7.00 CNY
Jan 1, 2024
7.00 CNY
Jan 1, 2025
7.00 CNY
The Jafron Biomedical Co AAQS history
YEARAAQSYoY
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
7—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

The AAQS of Jafron Biomedical Co is 7 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co